INTRODUCTION
Autologous hematopoietic SCT (AHSCT) is an important treatment for hematologic malignancies. In patients with relapsed lymphoma or multiple myeloma in first or second remission, it can improve PFS as well as OS. [1] [2] [3] [4] Key to the feasibility of AHSCT is the number of CD34 þ cells/kg body weight transplanted. Higher cell doses, particularly 45 Â 10 6 CD34 þ cells/kg, accelerate recovery of marrow function; conversely, lower cell doses, particularly o2 Â 10 6 CD34 þ cells/ kg, delay count recovery, increasing the risk of infection and other complications, and may even result in engraftment failure. [5] [6] [7] [8] Many factors influence the number of CD34 þ cells collected, including advanced age, previous radiation or chemotherapy, hypocellular marrow, marrow involvement, history of mobilization failure and mobilization method. [9] [10] [11] [12] Administration of growth factors and/or chemotherapy are two of the most common methods used to mobilize hematopoietic cells. G-CSF induces myeloid hyperplasia and release of CD34 þ cells into the circulation through proteolytic cleavage of adhesion molecules. 13 This can be enhanced with the addition of chemotherapy, though trade-offs exist in terms of efficiency, safety and cost. 14 For example, mobilization with chemotherapy þ G-CSF may improve CD34 þ cell collections, 15, 16 but increase the incidence of neutropenic fever 17 and infections. 18 Our purpose is to better characterize the outcomes of mobilization with chemotherapy þ G-CSF (C þ G) vs G-CSF alone.
Previous reports in the literature primarily focus on a single institution or rely on resource-use data from the 1990's. Our goal is to gain a sense of real-world practices and outcomes by reviewing the recent experiences of 11 institutions across the United States, with patients suffering from lymphoma or multiple myeloma who underwent AHSCT. In particular, we are interested in the number of cells collected, number of days of apheresis required, need for re-mobilization, time to engraftment, toxicity, resource utilization and cost.
MATERIALS AND METHODS

Patient selection
We performed a retrospective chart review at 11 medical centers that conduct AHSCT for patients with lymphoma and multiple myeloma. At each center, we looked at consecutive patients with lymphoma and myeloma aged at least 18 years who underwent PBSC mobilization between 1 January 2006 and 31 December 2007. By focusing on these years, we hope to describe modern practices independent of the use of plerixifor. The goal was to enroll five patients with each disease from each site; due to cost limitiations, we felt that including more sites would be more representative than including more subjects from each site. Patients were selected chronologically (for example, starting 1 January 2006), independent of mobilization method or other factors. If a site contributed additional patients, selection continued chronologically. Individuals were excluded if they participated in an AHSCT trial or if they received plerixafor (Mozobil) between 1 January 2006 and 31 December 2007. Additionally, chemomobilization regimens that made use of induction/salvage chemotherapy or multiple cycles of chemotherapy for mobilization purposes were excluded due to selection bias and difficulties in comparing outcomes between these groups. Chemomobilization refers to the administration of chemotherapy (typically, a CY-based regimen) with G-CSF for the primary purpose of mobilization, as opposed to chemotherapy administered for purposes of re-induction or salvage. Protocols were at the discretion of individual institutions. Stem cell collection practices and related outcomes were analyzed separately by disease and mobilization method, that is, lymphoma patients mobilized with C þ G (L:C þ G) vs G-CSF alone (L:G), and myeloma patients mobilized with C þ G (M:C þ G) vs G-CSF alone (M:G).
Institutional 
Cell dose
For the purpose of this study, the cell dose target for transplantation was at least 2 Â 10 6 CD34 þ cells/kg, and the ideal cell dose was considered to be at least 5 Â 10 6 CD34 þ cells/kg. However, goals were subject to individual physician's discretion, and in rare cases, if 2 Â 10 6 CD34 þ cells/kg were not available despite repeated mobilizations, patients may still proceed to transplant. Peripheral blood CD34 þ cell count was not always checked prior to initiating apheresis.
Engraftment
Neutrophil engraftment is defined as the first of the 3 consecutive days, on which the ANC exceeded 500 cells/mL. Platelet engraftment was defined as the first of the 7 days, on which the platelet count exceeded 20 000/mL without transfusion.
Costs
The costs of mobilization, apheresis, transplant and complications were calculated using the Center for Medicare and Medicaid Standards, as adapted from Shaughnessy et al. 19 Transplantation costs were separated for inpatient and outpatient transplants. Specific drug costs not available there were obtained from the 2010 Red Book. 20 Chemotherapy used specifically for mobilization purposes (for example, CY) was included in the cost of mobilization; chemotherapy that was part of a salvage regimen was excluded. Table 1 lists these costs in detail.
Statistical methods
Statistical differences between chemomobilized patients and patients mobilized with G-CSF alone were determined by the Yate's w 2 -test for categorical variables, and by an unpaired, two-tailed t-test and Mann-Whitney for continuous variables. Ninety-five percent confidence intervals were calculated as the mean ± 1.96 (s.d./On).
RESULTS
Patients
Data were collected for 226 consecutive patients across 11 centers. Details are provided in Table 2 . Sixty-four had lymphoma (28%) and 162 had multiple myeloma (72%); lymphoma subtypes include Hodgkin disease (9 patients treated with C þ G, 10 with G-CSF alone), anaplastic large cell (2, 0), Burkitt's (1, 0), diffuse large cell (6, 8) , follicular (8, 2), mantle cell (5, 7), peripheral T-cell (2, 1), primary central nervous system (1, 0), Waldenstrom's (0, 1) and other (1, 0). Overall, 35 lymphoma patients (55%) and 108 multiple myeloma patients (66%) received C þ G; the remainder received G-CSF alone. The majority of patients were male (132, 58%) and Caucasian (178, 79%). Seventy percent of patients with lymphoma and 36% with multiple myeloma had relapsed/ refractory disease.
Mobilization regimens
Mobilization protocols were at the discretion of individual sites and physicians. For chemomobilization, almost all patients were treated with a CY-based regimen (97% lymphoma, 83% of myeloma), the majority at a dose of 3 g/m 2 (71 and 49%), occasionally in combination with rituximab or etoposide, with some receiving dexamethasone. The median time when G-CSF was started post chemotherapy was 3 days for lymphoma patients and 4 days for myeloma patients. A median dose of 10 mg/kg G-CSF was used in all groups, given for a median of 10 days with chemomobilization and 6 days with G-CSF alone (Po0.001).
Stem cell mobilization and apheresis
Both C þ G and G-CSF alone successfully mobilized stem cells, with nearly all patients yielding at least 2 Â 10 6 CD34 þ cells/kg (Table 3 ). Patients mobilized with C þ G had to wait a week longer between mobilization and apheresis than patients mobilized with G-CSF alone (median wait for L:C þ G: 11 days vs L:G: 4 days, Po0.00001; M:C þ G: 12 days vs M:G: 4 days, Po0.00001). However, the median number of CD34 þ cells collected was similar for lymphoma patients mobilized with C þ G and G-CSF alone (6.6 Â 10 6 vs 5.5 Â 10 6 cells/kg, P ¼ 0.30), and higher for multiple myeloma patients mobilized with C þ G vs G-CSF alone (13.8 Â 10 6 vs 6.8 Â 10 6 cells/kg, Po0.001). A median of 10 L blood volume/patient were processed for L:C þ G, 20 L for L:G (Po0.001), 12 L for M:C þ G and 18.65 L for M:G (Po0.001). After 2 days, 69% of L:C þ G patients met their collection goal vs 53% of L:G (P40.05), and 77% of M:C þ G vs 57% of M:G (Po0.05) ( Table 4 ). Patients mobilized with C þ G yielded more cells/kg/day on average (L:C þ G: 5.51 Â 10 6 cells/kg collected on day 1 vs L:G: 2.92 Â 10 6 cells/kg, P ¼ 0.0231; MM:C þ G: 14.16 Â 10 6 cells/kg vs M:G: 3.69 Â 10 6 cells/kg, Po0.00001) and required fewer days of apheresis on average (L:C þ G: 2.11 vs L:G: 2.96 days, P ¼ 0.012; M:C þ G: 2.02 vs M:G: 2.83 days, P ¼ 0.0015).
Patients mobilized with C þ G tended to require fewer rounds of mobilization: 97% of L:C þ G required only one mobilization vs 83% of L:G, and 95% of M:C þ G vs 85% of M:G. Few patients required three or more rounds of mobilization: 3% of L:C þ G vs 7% of L:G; 1% of M:C þ G vs 4% M:G. None of these differences was statistically significant (all P40.05).
Engraftment
Eight patients did not proceed to transplant: three due to inadequate However, there were no significant differences in documented infections or sepsis (L:C þ G 0% vs L:G 4%; M:C þ G 6% vs M:G 14%, all P40.05) (note: some patients may have had a documented infection without having a fever and neutropenia). Requirement for a new apheresis catheter were also similar (L:C þ G 2% vs L:G 0%; M:C þ G 6% vs M:G 4%, all P40.05).
Interestingly, patients mobilized with C þ G tended to have less complicated transplant courses, although most of these differences were not statistically significant (Figure 1 ). There was a trend toward less mucositis (L:C þ G 26% vs L:G 50%; M:C þ G 17% vs M:G 27%, P40.05 for both), although similar numbers of days of pain medication were required (median 7 days for L:C þ G vs 11 for L:G, P ¼ 0. Costs Mobilization with C þ G was more resource-intensive (Table 5) , particularly with regard to antibiotics, antifungals, antivirals and pain medications (note: we did not distinguish between prophylactic and therapeutic use). However, use of these medications did not contribute significantly to cost; rather, the primary drivers of the increased cost of chemomobilization were chemotherapy and extra days of G-CSF (Supplementary Figure 2S ): median cost for L:C þ G was $10 300 vs $7300 for L:G (Po0.001); median cost for M:C þ G was $8800 vs $5600 for M:G (Po0.001) ( Table 6 ). For the 19 patients who required re-mobilization, median costs were increased by $6700 (mean $5500, 95% confidence interval (CI) $4500-$6400) on top of additional apheresis costs. Overall median costs of apheresis were similar: L:C þ G $8200 vs L:G $7800 (P ¼ 0.422) and M:C þ G $8200 vs M:G $8300 (P ¼ 0.456). Whereas C þ G was associated with fewer days of apheresis on average, the median number of days of apheresis was 2 for both C þ G and G, therefore not affecting median costs. Transplant costs were calculated separately for patients who received their transplants as inpatients vs outpatients (Supplementary Figure 3S) . For outpatient transplants, median costs for L:C þ G (n ¼ 5, 14%) were $22 900; no L:G patients were transplanted as oupatients. Median outpatient transplant costs for M:C þ G (n ¼ 63, 60%) were $28 000 vs $37 000 for M:G (n ¼ 15, 29%) (P ¼ 0.017). For inpatient transplants, median costs for L:C þ G (n ¼ 30, 86%) were $65 600 vs $70 600 for L:G (n ¼ 28, 100%) (P ¼ 0.549); median costs for M:C þ G (n ¼ 42, 40%) were $60 700 vs $60 900 for M:G (n ¼ 36, 71%) (P ¼ 0.449).
Overall, for outpatient transplants, median total costs combining mobilization, apheresis and transplant for L:C þ G (n ¼ 5, 14%) were $39 700; no L:G patients were transplanted as oupatients, and median total costs for outpatient transplants with M:C þ G (n ¼ 63, 60%) were $45 600 vs $51 400 for M:G (n ¼ 15, 29%) (P ¼ 0.403). For inpatient transplants, median costs for L:C þ G (n ¼ 30, 86%) were $81 600 vs $88 200 for L:G (n ¼ 28, 100%) (P ¼ 0.703); median costs for M:C þ G (n ¼ 42, 40%) were $78 100 vs $77 200 for M:G (n ¼ 36, 71%) (P ¼ 0.924).
DISCUSSION
This retrospective, multi-institution review compared C þ G vs G-CSF alone and found significant differences in mobilization results, but similar overall outcomes. Whereas C þ G costed more and required patients to wait an additional 7-8 days before the cells could be collected, an average of 1 less day of apheresis was required, as more cells were collected per day, and although differences were not statistically significant, there was a trend toward a lower frequency of re-mobilization with C þ G. Outcomes with transplant including engraftment and cost tended to be similar, regardless of mobilization method. Although there was a trend to less transplant-related toxicities with C þ G, it is difficult to determine if there is a true difference as a result of mobilization method or if this is due to other confounders (for example, disease burden, inpatient vs outpatient transplant, and so on). Although outpatient transplants for myeloma after mobilization with C þ G cost less than outpatient transplants after G-CSF alone, it is unclear from our study if this is an effect of mobilization method or other confounders, and there was no difference in total costs. Results were otherwise comparable whether patients had lymphoma or multiple myeloma.
Inadequate stem cell mobilization results in increased resource consumption and costs. 21 Although C þ G increased yields compared with G-CSF, we found that this advantage was more than offset by the increased resource utilization and costs of 
Chemomobilization vs G-CSF AD Sung et al chemotherapy itself, and increased complications like febrile neutropenia. However, as each additional day of apheresis may increase costs by as much as $6600 22 on top of the additional mobilization costs of chemotherapy and G-CSF as noted above, it may be more cost-effective to treat patients at risk of inadequate mobilization with C þ G. Our findings are similar to other studies where the cost of mobilization with G-CSF was $5760 23 and that of C þ G was $10 605. 24 This study is limited by its retrospective design. It is possible that the differences in stem cell collection were due to biases related to patient selection, patient referral, center experience and practice, plans for single vs tandem transplantation, as well as a number of other possible variables. Unfortunately, we were not able to capture data for all these potential confounders. In addition, the selection of chemomobilization may, in part, be for the treatment of the underlying malignancy, and as such its use may not be completely comparable to mobilization with G-CSF alone. We do not have data on how this or other known predictors of poor mobilization such as thrombocytopenia may have had an impact on mobilization. This study did not follow relapse rates after transplant, therefore we are unable to comment as to whether C þ G reduces the rate of relapse compared with G-CSF alone. Finally, the wide array of chemotherapy regimens used in this study makes it difficult to generalize outcomes. Nonetheless, this study provides a useful snapshot of practices and outcomes from multiple institutions across the country.
Although we did not look at plerixafor, a small molecule CXCR4 antagonist that can enhance the mobilization of PBSCs, it is worth noting that the addition of this agent to G-CSF can increase CD34 þ yields compared with G-CSF alone in patients with multiple myeloma 25 and lymphoma. 26 Historical comparison to CY þ G-CSF report similar numbers of cells collected, costs and clinical outcomes. 27 Several studies have looked at the optimal use of plerixafor in terms of both timing and cost effectiveness. [28] [29] [30] In summary, C þ G improves stem cell collection but there are trade-offs, particularly with regard to cost. These may be offset in patients at high risk of inadequate mobilization; such a strategy has been advocated for the selective use of plerixafor. Although our study provides a real-world look at practices and outcomes across multiple institutions, prospective randomized studies looking at C þ G compared with G-CSF alone as well as plerixafor þ G-CSF would further our knowledge and understanding of optimal and cost-effective methods of mobilization.
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